Shanghai RAAS Bets on Innovative Drugs as Blood Products Face Pricing Pressure
TREE NEWS reports: Shanghai RAAS Blood Products reported a sharp decline in third-quarter earnings, underscoring the mounting pressure on China’s blood products industry. For the quarter ended September, revenue fell 18.9% year-over-year to 1.735 billion yuan, while net profit attributable to shareholders dropped 27.93% to 318 million yuan. The results, disclosed on October 27, reflect a sector-wide adjustment driven by centralized procurement and increased market supply.
Peer company Pacific Shuanglin Bio-pharmacy also posted weak results, with Q3 revenue down 9.24% to 573 million yuan and net profit plunging 45.63% to 66 million yuan. The industry is grappling with high channel inventory and downward pricing pressure, prompting companies to rethink their strategies.
Market Implications
Shanghai RAAS acknowledged that it has deliberately stepped back from price-for-volume tactics and is prioritizing actual terminal sales over shipment growth. This shift, while prudent for long-term health, is weighing on near-term revenue and profit. The company noted that terminal sales of its self-produced blood products grew by double digits in the first nine months, and channel inventory has begun to decline.
Despite the traditional business headwinds, Shanghai RAAS is making a strategic push into innovative drugs. In September, the company completed registration for a Phase III clinical trial of SR604, a hemophilia drug candidate designed to prevent bleeding. SR604 is a first-in-class monoclonal antibody targeting activated protein C (APC), with no similar products approved globally. The hemophilia treatment market in China is projected to reach 14.1 billion yuan by 2030.
To support commercialization, Shanghai RAAS signed an agreement in September to acquire 100% equity of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd., gaining a 6,000-liter commercial manufacturing facility in Zhangjiang, Shanghai. This site will be used for clinical sample preparation and future commercial production of SR604.
However, the path from clinical trials to market approval is lengthy and fraught with uncertainties, including regulatory hurdles and competitive pressures. For investors, the key question is whether the innovative drug pipeline can offset the ongoing weakness in the core blood products business.
Key Takeaways
- Shanghai RAAS and peers face declining revenues and profits due to industry-wide pricing pressure and inventory destocking.
- The company is pivoting toward innovative drugs, with SR604 and a new manufacturing facility, but commercialization is years away.
- Near-term performance hinges on the recovery of the blood products market; investors should monitor channel inventory and pricing trends.
